logo
Plus   Neg
Share
Email

TAG Immobilien To Buy Vantage Development

TAG Immobilien AG said that it signed an investment agreement to buy 100% of the shares in Vantage Development S.A. with a simultaneous carve-out of its commercial real estate business which will be repurchased by the selling shareholders.

Based on a tender offer price of PLN 11.50 per share, the total transaction consideration amounts to 131 million euros, of which 46 million euros relate to the commercial real estate business unit.

As a result, the total net consideration for TAG amounts to 85 million euros for the residential business and platform of Vantage Development. The total transaction consideration will be fully paid by TAG's existing cash.

The company expects to close the transaction in the first-quarter of 2020. After completion of the transaction, the company plans to delist Vantage Development's shares, currently listed on the Warsaw Stock Exchange.

Vantage Development is a real estate developer focused on the economically strong region of Wroclaw in the western part of Poland with proven track record of more than 4,000 units completed and delivered.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
Follow RTT
>